HIK - Hikma Pharmaceuticals PLC
LSE
->
Healthcare
->
Drug Manufacturers—Specialty & Generic
London,
United Kingdom
Type: Equity
HIK price evolution
HIK
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $205 | $205 | $272 | $272 |
| Short term investments | ||||
| Net receivables | $873 | $873 | $905 | $905 |
| Inventory | $891 | $891 | $859 | $859 |
| Total current assets | $2100 | $2100 | $2176 | $2176 |
| Long term investments | $10 | $10 | $51 | $51 |
| Property, plant & equipment | $1141 | $1141 | $1087 | $1087 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $4680 | $4680 | $4619 | $4619 |
| Current liabilities | ||||
| Accounts payable | $568 | $568 | $505 | $505 |
| Deferred revenue | ||||
| Short long term debt | $161 | $161 | $221 | $221 |
| Total current liabilities | $1339 | $1339 | $1215 | $1215 |
| Long term debt | $1030 | $1030 | $1091 | $1091 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $2471 | $2471 | $2417 | $2417 |
| Shareholders' equity | ||||
| Retained earnings | $2158 | $2158 | $2146 | $2146 |
| Other shareholder equity | -$271 | -$271 | -$266 | -$266 |
| Total shareholder equity | $2209 | $2209 | $2202 | $2202 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $205 | $270 | $426 | $120 |
| Short term investments | $273 | $227 | ||
| Net receivables | $873 | $841 | $876 | $734 |
| Inventory | $891 | $776 | $695 | $757 |
| Total current assets | $2100 | $1999 | $2094 | $1922 |
| Long term investments | $10 | $52 | $57 | $34 |
| Property, plant & equipment | $1141 | $1081 | $1146 | $1068 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $4680 | $4471 | $4372 | $4135 |
| Current liabilities | ||||
| Accounts payable | $568 | $291 | $262 | $279 |
| Deferred revenue | ||||
| Short long term debt | $161 | $148 | $121 | $168 |
| Total current liabilities | $1339 | $1077 | $1016 | $1028 |
| Long term debt | $1030 | $1135 | $725 | $764 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $2471 | $2323 | $1919 | $2000 |
| Shareholders' equity | ||||
| Retained earnings | $2158 | $2092 | $2129 | $2011 |
| Other shareholder equity | -$271 | -$266 | -$224 | -$199 |
| Total shareholder equity | $2209 | $2148 | $2453 | $2135 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $724 | $724 | $713.5 | $713.5 |
| Cost of revenue | $386.5 | $386.5 | $356 | $356 |
| Gross Profit | $337.5 | $337.5 | $357.5 | $357.5 |
| Operating activities | ||||
| Research & development | $42.5 | $42.5 | $32 | $32 |
| Selling, general & administrative | $144.5 | $144.5 | $130.5 | $130.5 |
| Total operating expenses | $566.5 | $566.5 | $559 | $559 |
| Operating income | $157.5 | $157.5 | $154.5 | $154.5 |
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $9 | $9 | $35.5 | $35.5 |
| Interest expense | -$23 | -$23 | -$22 | -$22 |
| Net income | ||||
| Net income | $29.5 | $29.5 | $65.5 | $65.5 |
| Income (for common shares) | $29.5 | $29.5 | $65.5 | $65.5 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $2875 | $2517 | $2553 | $2341 |
| Cost of revenue | $1485 | $1252 | $1252 | $1128 |
| Gross Profit | $1390 | $1265 | $1301 | $1213 |
| Operating activities | ||||
| Research & development | $149 | $144 | $143 | $137 |
| Selling, general & administrative | $550 | $509 | $488 | $464 |
| Total operating expenses | $2251 | $1926 | $1955 | $1739 |
| Operating income | $624 | $591 | $598 | $602 |
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $89 | $42 | $124 | $128 |
| Interest expense | -$90 | -$59 | ||
| Net income | ||||
| Net income | $190 | $188 | $421 | $431 |
| Income (for common shares) | $190 | $188 | $421 | $431 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | $29.5 | $29.5 | $65.5 | $65.5 |
| Operating activities | ||||
| Depreciation | $14.5 | $14.5 | $36.5 | $36.5 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | $193 | $193 | $111 | $111 |
| Investing activities | ||||
| Capital expenditures | -$42.5 | -$42.5 | -$42 | -$42 |
| Investments | ||||
| Total cash flows from investing | -$107 | -$107 | -$59.5 | -$59.5 |
| Financing activities | ||||
| Dividends paid | -$27.5 | -$27.5 | -$41 | -$41 |
| Sale and purchase of stock | ||||
| Net borrowings | -$63.5 | -$63.5 | $12 | $12 |
| Total cash flows from financing | -$119.5 | -$119.5 | -$49 | -$49 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$33.5 | -$33.5 | $1 | $1 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | $190 | $188 | $544 | $558 |
| Operating activities | ||||
| Depreciation | $102 | $182 | $145 | $91 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | $608 | $530 | $638 | $464 |
| Investing activities | ||||
| Capital expenditures | -$169 | -$138 | -$229 | -$224 |
| Investments | ||||
| Total cash flows from investing | -$333 | -$607 | -$238 | -$283 |
| Financing activities | ||||
| Dividends paid | -$137 | -$125 | -$120 | -$109 |
| Sale and purchase of stock | -$300 | -$375 | ||
| Net borrowings | -$103 | $447 | -$114 | $220 |
| Total cash flows from financing | -$337 | -$58 | -$287 | -$298 |
| Effect of exchange rate | -$7 | -$10 | -$2 | |
| Change in cash and equivalents | -$65 | -$156 | $103 | -$119 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | N/A |
| Revenue | $2.88B |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | $190.00M |
| Revenue Q/Q | 11.04% |
| Revenue Y/Y | 14.22% |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | 4.09% |
| ROE | 8.61% |
| Debt/Equity | 1.12 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 1.57 |
| Quick ratio | 0.90 |